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Objectives. This study was conducted to determine whether vaccination with the quadrivalent human
papillomavirus (HPV) vaccine after loop electrosurgical excision procedure (LEEP) for high-grade cervical
intraepithelial neoplasia (CIN2–3) is effective in preventing recurrence of CIN2–3.
Methods. Between August 2007 and July 2010, 737 patients aged 20–45 years who were diagnosed with
CIN2–3 were treated by LEEP and followed. Three hundred and sixty patients were vaccinated with the quad-
rivalent HPV vaccine after LEEP (vaccination group), and 377 patients were followed without vaccination
(non-vaccination group). The vaccination group received the ﬁrst dose at 1 week after LEEP and the
remaining two doses two and six months later. Post-LEEP follow-up was performed at 3, 6, 9, 12, 18, and
24 months during the ﬁrst 2 years and yearly thereafter.
Results. Irrespective of causal HPV type, 36 (4.9%) patients developed recurrence. In the vaccination group
(360 patients), 9 patients (2.5%) developed recurrence, whereas 27 patients (7.2%) in the non-vaccination
group (377 patients) developed recurrence. In patients infected with HPV of 16 and/or 18 type, 5 patients
(2.5%) in the vaccination group (197 patients) and 18 patients (8.5%) in the non-vaccination group (211
patients) developed recurrent disease related to vaccine HPV types (HPV 16 or 18 types) after LEEP (P b 0.01).
Multivariate analysis showed that no vaccination after LEEP was an independent risk factor for recurrent
CIN2–3 (HR = 2.840; 95% conﬁdence interval, 1.335–6.042; P b 0.01).
Conclusions. Vaccination with the quadrivalent HPV vaccine after treatment may be considered in
preventing recurrence of CIN2–3.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
High-grade cervical intraepithelial neoplasia (CIN2–3) bears a risk of
developing invasive carcinoma if left untreated [1]. Persistent high-risk
human papillomavirus (HR-HPV) infections aremore strongly associatedGynecology, ChonnamNational
Republic of Korea. Fax: +82 62
).
nc. Open access under CC BY license.with the development of CIN2–3, and are considered the ﬁrst step in the
progression to cervical carcinoma [2]. Conservative treatmentwith a loop
electrosurgical excision procedure (LEEP) is both a diagnostic and
therapeutic procedure that can effectively eradicate CIN2–3 [3,4].
However, residual/recurrent disease after a LEEP varies between 5%
and 30%, requiring follow-up and retreatment once lesions have
been identiﬁed [5–7].
The currently available human papillomavirus (HPV) vaccines based
on recombinant virus-like particles are designed to prevent HPV associ-
ated disease. Both the quadrivalent vaccine (against HPV types 6, 11, 16,
and 18) and the bivalent vaccine (against types 16 and 18) are highly
effective in preventing CIN2–3 or adenocarcinoma in situ in women
aged 16–26 years, who are not infected with the relevant HPV type
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the same efﬁcacy of the quadrivalent HPV vaccine in susceptible
women aged 24–45 years [11].
In a recent study, previous vaccination with the quadrivalent HPV
vaccine among women who had surgical treatment for HPV related
disease signiﬁcantly reduced the incidence of subsequent HPV related
disease, including high grade disease [12]. However, no studies to date
have looked at the impact of HPV vaccination in preventing subsequent
disease after treatment of CIN2–3.
This study was conducted to determine whether vaccination with
the quadrivalent HPV vaccine among patients aged 20–45 years after
LEEP for CIN2–3 is effective in preventing recurrent disease.Methods
We retrospectively reviewed the records of all 748 patients aged
20–45 years with histologically-conﬁrmed CIN2–3 who had been
treated by LEEP at the Department of Obstetrics and Gynecology of
Chonnam National University Hospital (CNUH) between August
2007 and July 2010. Seven hundred thirty-seven patients were con-
sidered eligible for the study if they fulﬁlled the following criteria:
(a) histologically-conﬁrmed CIN2–3 by LEEP, (b) patients in whom
both pre- and post-LEEP HR-HPV test results from the HPV DNA chip
test (HDC; MyGene Co., Seoul, South Korea) and the hybrid capture II
assay (HC2; Digene Co., Gaithersburg, MD, USA), (c) patients who
have not received the HPV quadrivalent vaccine or the bivalent vaccine
before diagnosis with CIN2–3, and (d) patients whowere followed for a
minimum of 2 years.We excluded 5 patients who underwent hysterec-
tomy after LEEP and 6 patients with residual CIN2–3.
LEEP was performed under local anesthesia using wire loop elec-
trodes with a diathermy apparatus set. A section was placed at the
12 o'clock position of the LEEP specimen for orientation, and then
specimens were ﬁxed in 10% formalin for pathological examination.
We discussed with patients about the rationale of post-treatment
vaccination after LEEP. Some patients agreed and others disagreed
with vaccination after LEEP. Three hundred and sixty patients received
quadrivalent HPV vaccination (vaccination group) and 377 patients did
not receive quadrivalentHPV vaccination (non-vaccination group) after
LEEP for CIN2–3. Patients who agreedwith the quadrivalent HPV (types
6, 11, 16, and 18) L1 virus-like particle vaccine (Gardasil, Merck,
Whitehouse Station, NJ, USA) received the ﬁrst dose at 1 week after
LEEP and the remaining two doses 2 and 6 months later. The patients
underwent post-operative examination at 3, 6, 12, 18, and 24 months
during the ﬁrst 2 years and yearly thereafter. At every visit after LEEP,
HPV DNA tests (HC2 and HDC) and cytology were performed on all
patients, and colposcopy/endocervical sampling was carried out if the
HPV DNA test was positive or if repeat cytology revealed atypical
squamous cells of undetermined signiﬁcance or greater. If CIN2–3 was
reported histologically at the margins of an excised specimen or in
an endocervical sample obtained immediately after LEEP, endocervical
sampling was performed at 3 and 6 months. Colposcopic directed
punch biopsies of the cervix were taken in the case of any suspected
area after application of 5% acetic acid. When the lesion was not vis-
ible or only partially visible, additional endocervical curettage was
performed.
Criteria for residual or recurrent disease were based on positive
histology of colposcopy-directed biopsy or endocervical curettage.
Patients with histologically-conﬁrmed CIN2–3 at 3 month follow-up
after treatment were considered as having residual disease. Patients di-
agnosedwith CIN2–3 on biopsies at the next follow-up (from 6 months
onward) were considered as having recurrent disease. For statistical
analysis, the results of cervical biopsies obtained during follow-up
were grouped as negative in the presence of normal/cervicitis or CIN1
and positive in the presence of CIN2 or CIN3. Positive histologic
results during follow-up were considered as recurrent disease. Thestudy protocol was evaluated and approved by the Institutional
Review Board at CNUH.
Hybrid capture II assay
The sample was collected by placing a cytobrush into the exocervix
and rotating the brush 3 times; the samplewas kept frozen at−20 °C in
a collection tube (Digene Co) until needed. The denatured single-strand
DNA was hybridized with a RNA researcher of a mixed HR-HPV group.
This reaction mixture was placed in a microtiter well coated with anti-
bodies for the RNA/DNA hybrid. After RNA/DNA hybrid-antibody bond-
ing, the mixture was reacted with alkaline phosphatase-conjugated
antibodies, washed, and lumi-Phospho 530 was added to react with
the dioxetane-based chemiluminescent substrate. Alkaline phospha-
tase was added to obtain luminescent light, which was measured with
a luminometer and expressed in relative light unit. The solution
containing 1 pg/mL of HPV-16 DNA was used as a positive control
group for the HR-HPV group. The relative light unit for all the samples
was set to the degree of relative brightness in comparison with the
positive control group. This ratio was considered positive when it was
1.0 or greater and negative when it was 1.0 or less. The samples were
analyzed for the presence of 13 types of the HR-HPV group (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68).
HPV DNA chip test
We used the HD-C, a PCR-based DNA microarray system as a HPV
genotyping method for HPV typing. The HD-C contains 24 type-speciﬁc
probes; 15 probes are HR types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, and 68) and 9 probes are LR types (6, 11, 34, 40, 42, 43, 44,
54, and 70). Brieﬂy, DNA was isolated from a swab sample using a DNA
isolation kit (MyGene Co.), and then target L1 regions of HPV DNA were
ampliﬁed and labeled by a single dye (indocarbocyanine-dUTP; NEN
Life Science Products, Inc., Boston, MA, USA). The PCR products of all
samples were detected by electrophoresis with a 2.5% agarose gel. The
samplesweremixedwith ahybridization solution (MyGeneCo.). Hybrid-
izationwas performed at 43 °C for 90 min. The hybridized HPVDNAwas
visualized using a DNA chip scanner (Scanarray Lite; GSI Lumonics®,
Ottawa, Ontario, Canada). Fifteen types of HR-HPV positivity were used
to assess HDC performance.
Statistical analysis
Statistical comparison was carried out using Student's t-test or
Fisher exact test. Agreement between tests was assessed by Cohen's
kappa statistic and P values were calculated using McNemar's test,
with values between 0.00 and 0.20 indicating poor agreement,
values between 0.21 and 0.40 indicating fair agreement, values be-
tween 0.41 and 0.60 indicatingmoderate agreement, values between
0.61 and 0.80 indicating substantial agreement, and values between
0.81 and 1.00 indicating near-perfect agreement. Variables showing
a signiﬁcant association with survival were included in multivariate
analysis based on the Cox proportional-hazard model. Step-wise
regression techniques were used to build multivariate models
using a signiﬁcance level of 0.10 to remain in the model. Statistical
analyses were performed using SPSS software (version 19.0; SPSS,
Inc., Chicago, IL, USA). Ninety-ﬁve percent conﬁdence intervals
were calculated. All reported P values are two-sided, and P values
b0.05 were considered statistically signiﬁcant.
Results
Epidemiologic data, HR-HPV test data from the HDC and HC2, and
pathology data were obtained from the patients' medical records. The
mean age of all 737 patients was 36.7 years. Of these, 36 patients
(4.9%) were aged 20–26 years, 255 patients (34.6%) aged 27–35 years
Table 3
HR-HPV genotypes by HDC before LEEP.
Vaccination
group
N = 360
Non-vaccination
group
N = 377
Total
N = 737
None (N = 15) 7/15 8/15 15
Vaccine HR-HPV genotype
(N = 408)
16 159/197 173/211 332/408
18 28/197 26/211 54/408
16 + 18 10/197 12/211 22/408
Non-vaccine HR-HPV genotype
(N = 314)
31 19/156 18/158 37/314
33 13/156 16/158 29/314
35 6/156 8/158 14/314
39 1/156 3/158 4/314
45 2/156 3/158 5/314
51 1/156 4/158 5/314
52 22/156 22/158 44/314
53 4/156 7/158 11/314
56 2/156 4/158 6/314
58 47/156 49/158 96/314
66 4/156 2/158 6/314
68 4/156 4/158 8/314
Multiple infection excluding 16 or 18 31/156 18/158 49/314
LEEP, loop electrosurgical excision procedure; HR, high risk; HPV, human papillomavi-
rus; HDC, HPV DNA chip test.
Table 1
Patient characteristics.
Vaccination
group
N = 360
Non-vaccination
group
N = 377
P
Age (years) 0.935
Mean ± SD 36.70 ± 6.00 36.67 ± 5.66
Range 21–45 20–45
Initial cytology 0.301
ASCUS 60 48
LSIL 32 38
HSIL 268 291
CIN at LEEP 0.198
CIN2 54 71
CIN3 306 306
Cone margin 0.578
Negative 297 304
Positive 63 73
Endocervical cytology 0.711
Negative 344 357
Positive 16 20
Baseline HPV 16 or 18 by HDC 0.790
Negative 163 166
Positive 197 211
SD, standard deviation; ASCUS, atypical squamous cells of undetermined signiﬁcance;
LSIL, low squamous intraepithelial lesion; HSIL, high squamous intraepithelial lesion;
CIN, cervical intraepithelial neoplasia; LEEP, loop electrosurgical excision procedure;
HPV, human papillomavirus; HDC, HPV DNA chip test.
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ﬁrmed by histology; 125 patients had CIN2, and 612 patients had
CIN3. A total of 737 patients were enrolled with a median follow-up
time of 3.5 years. Of the 737 patients, 36 (4.9%) developed recurrence
during the follow-up period; histology revealed 6 cases of CIN2
(24.3%) and 30 cases of CIN3 (75.7%). The mean lag time between
LEEP and the diagnosis of recurrent disease was 14.8 months (range,
6–48 months). Of the 737 patients included in the analysis, 360 patients
received quadrivalent HPV vaccination and 377 patients did not receive
quadrivalent HPV vaccination after LEEP for CIN2–3.
Baseline demographic characteristics were very much similar
between patients in the vaccination and non-vaccination groups
with respect to age, cytologic abnormalities, CIN grade, cone margin
involvement, and positive endocervical cytology at the time of LEEP.
Baseline HPV positivity to HPV 16 or 18 was not signiﬁcantly differ-
ent in the group of patients with vaccination and non-vaccination
(P = 0.790) (Table 1).
The concordance and discordant results between the 2 HPV tests are
summarized in Table 2. The overall agreement between the 2 tests was
98.5%, with a kappa value of 0.659. Of 719 HR-HPV-positive specimens
by the HC2, the HDC was positive in 715 specimens (99.4%). Among 18
patients who were negative by the HC2, the HDC was negative in 11
patients (61.1%). When the HDC was compared to the HC2, discordant
results were observed among 11 (1.5%) patients, comprising 4 HC2-
positive/HDC-negative and 7 HC2-negative/HDC-positive results.Table 2
The level of concordance between HR-HPV tests.
No. of specimens (%) with
HDCa
Total no. of specimens (%)
Negative Positive
HC2a
Negative 11 7 18 (2.4)
Positive 4 715 719 (97.6)
Total 15 (2.0) 722 (98.0)
HR, high risk; HPV, human papillomavirus; HC2, hybrid capture II test; HDC, HPV DNA
chip test.
a Absolute agreement = 98.5%, kappa = 0.659 (P b 0.001). Agreement between tests
was assessed by Cohen's kappa statistic. P value was calculated using McNemar's test.Genotyping of 7 HC2-negative/HDC-positive cases revealed 3 HPV-53,
2 HPV-66, 1 HPV-16, and 1 HPV-18.
The distribution of prevalent HR-HPV genotypes by the HDC at the
time of LEEP is presented in Table 3. HPV DNA was found in 98.0%
(722/737) of the total cases. 55.4% (408/737) of patients with CIN2–3
related to HPV types 16 or 18 and 42.6% (314/737) were infected with
other HR-HPV types at baseline by HDC. Additionally, most patients
positive to vaccine-type HPV DNA were positive to only one HR-HPV
type (22 were infected with exactly two vaccine types).
Analysis of populations to determine the impact of quadrivalent
HPV vaccine after LEEP for CIN2–3 is shown in Fig. 1. Of 360 patients
in the vaccination group, 9 (2.5%) developed recurrence during the
follow-up period. Five (4 HPV-16 and 1 HPV-18) of 197 patients
(2.5%) were related to HPV 16 or 18, but 4 of 163 patients (2.5%) who
were unrelated toHPV 16 or 18 developed recurrence. Four of 5 patients
related to vaccine HPV types had cone margin involvement, and 2 of 4
patients unrelated to vaccine HPV types had cone margin involvement.
Of 377 patients in the non-vaccination group, 27 (7.2%) developed re-
currence during the follow-up period. Eighteen (13 HPV-16 and 5
HPV-18) of 211 patients (8.5%) were related to HPV 16 or 18, but 9 of
166 patients (5.4%) who were unrelated to HPV 16 or 18 developed re-
currence. Thirteen of 18 patients related to vaccine HPV types had cone
margin involvement, and 2 of 9 patients unrelated to vaccine HPV types
had cone margin involvement. With regard to patients related to vac-
cineHPV types, the non-vaccination group had a signiﬁcantly higher re-
currence rate than the vaccination group (8.5% and 2.5%, respectively;
P b 0.05). Regarding patients unrelated to vaccine HPV types, the
non-vaccination group had a slightly higher recurrence rate than the
vaccination group, but recurrence rates were not signiﬁcantly different
between patients in the non-vaccination and vaccination groups (5.4%
and 2.5%, respectively; P = 0.257). All 36 patients who developed re-
currence tested positive for the same HPV genotype as the type before
LEEP. None of the 22 patients who were positive to both HPV 16 and
18 developed recurrence.
Patients with recurrent disease did not differ from cured patients
with respect to age, previous cytologic abnormalities, and CIN grade
at the time of LEEP. Cone margin involvement, positive endocervical
cytology, and non-recipients with quadrivalent HPV vaccine were as-
sociated with a signiﬁcantly higher risk of recurrent disease (P b 0.01,
Table 4).
Fig. 1. Patient outcomes.
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(HR) was adjusted for covariates. The risk of recurrence was higher
for patients who did not receive the vaccine (HR = 2.840; 95% conﬁ-
dence interval [CI], 1.335–6.042; P b 0.01), with cone margin involve-
ment (HR = 4.869; 95% CI, 2.365–10.221; P b 0.01), and positive
endocervical cytology involvement (HR = 3.102; 95% CI, 1.363–7.062;
P = 0.01), as shown in Table 5.
Discussion
A previous study has demonstrated that LEEP is currently one of the
most common techniques for conization; it was described to effectively
eradiate CIN2–3 [3,4]. Although the natural history of untreated HPV
infection is well known, the progress of HPV infections after successful
treatment is poorly understood. Several reports have suggested that
successful conization also effectively eradicates HPV infections in most
patients with CIN [13,14], and that the persistence of high-risk HPV
infection at follow-up is a signiﬁcant predictor of residual or recurrent
CIN after conization. A study showed that HR-HPV infection clearance
after conization with clear resection margins was 92.6–95.7% at the
6 month follow-up [15,16]. In our previous study, 37 of 672 patients
(5.5%) developed residual/recurrent disease, and those who developed
residual/recurrent disease tested positive for the same HR-HPV geno-
type before and after LEEP. The same HR-HPV genotype by the HDC
during the follow-up period had a sensitivity and negative predictive
value of 100% for detecting residual/recurrent disease [17].
In the present study, 9 of 360 patients (2.5%) in the vaccination group
developed recurrent disease and 27 of 377 patients (7.2%) in the non-
vaccination group developed recurrent disease. All 36 patients who de-
veloped recurrence tested positive for the same HR-HPV genotype by
HDC.
The quadrivalent HPV vaccine is already proven for its beneﬁts in
women and girls aged 9–26 years [8,9]. In a recent study, the quadriva-
lent HPV vaccine was efﬁcacious in women aged 24–45 years whowere not infected with the relevant HPV types at enrolment [11]. The
quadrivalent HPV vaccine is effective in women up to the age of 45,
whereby prophylactic vaccine efﬁcacy against diseases related to vaccine
HPV types was 92.4% (49.6% to 99.8) [18]. Recently, Joura et al. [12]
reported that the vaccine was associated with a signiﬁcant reduction in
the risk of any subsequent high grade disease of the cervix by 64.9%
(20.1% to 86.3%). This study was an ad hoc analysis of FUTURE I and II
that the trials were not designed or powered to evaluate the effect of
vaccination after cervical surgery or diagnosis. Women with a prior
history of HPV related disease were excluded from enrollment, so this
study could not directly measure the vaccine's impact on women who
had undergone treatment before vaccination, since all women in that
study had been vaccinated before treatment.
No study has been done on the effect of prophylactic vaccination
given after treatment of CIN2–3 in women who missed the opportunity
of vaccination before developing the disease. Therefore, the aim of this
study was to determine whether the vaccination with quadrivalent
HPV vaccine among patients aged 20–45 years who had surgical treat-
ment for CIN2–3 is effective in protecting the recurrence of the disease.
This study was able to demonstrate statistically signiﬁcant efﬁcacy
against recurrent CIN2–3 in patients aged 20–45 years. Vaccination
signiﬁcantly reduced recurrent CIN2–3 after surgical treatment. In
patients related to vaccine HPV types, the non-vaccination group had a
signiﬁcantly higher recurrence rate than the vaccination group (8.5%
and 2.5%, respectively; P b 0.05). In patients unrelated to vaccine HPV
types, the non-vaccination group had slightly higher recurrence rate
than the vaccination group, but recurrence rates were not signiﬁcantly
different between patients in the non-vaccination and vaccination
groups (5.4% and 2.5%, respectively; P = 0.257). Base on the multivari-
ate Cox regression model, vaccination with the quadrivalent HPV
vaccine among patients aged 20–45 years after LEEP for CIN2–3 was
effective in preventing recurrent disease (P b 0.01), even after evalua-
tion of other factors, including positive endocervical cytology and posi-
tive cone margin. The implications of these ﬁndings are relevant to the
Table 4
Patient characteristics according to recurrence.
No recurrence
N = 701
Recurrence
N = 36
P
Age (years) 0.689
Mean ± SD 36.70 ± 5.79 36.29 ± 6.35
Range
Initial cytology 20–45 24–45 0.354
ASCUS 105 3
LSIL 68 2
HSIL 528 31
CIN at LEEP >0.99
CIN2 119 6
CIN3 582 30
Cone margin b0.01
Negative 586 15
Positive 115 21
Endocervical cytology b0.01
Negative 674 27
Positive 27 9
Vaccination b0.01
Recipients 351 9
Non-recipients 350 27
SD, standard deviation; ASCUS, atypical squamous cells of undetermined signiﬁcance;
LSIL, low squamous intraepithelial lesion; HSIL, high squamous intraepithelial lesion;
CIN, cervical intraepithelial neoplasia; LEEP, loop electrosurgical excision procedure.
Table 5
Progression-free survival analysis by the Cox model.
Hazards ratio (95% CI) P value
Cone margin
Positive versus negative 4.869 (2.365–10.221) b0.01
Endocervical cytology
Positive versus negative 3.102 (1.363–7.062) b0.01
Vaccination
Non-recipients versus recipients 2.840 (1.335–6.042) b0.01
CI, conﬁdence interval.
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underwent LEEP.
The HDC is a newly developed biotechnology which may be ap-
plied for the detection and typing of HPV. The accuracy of the HDC
for the detection and typing of HPV in cervical lesions by comparing
the results of HPV DNA sequencing with the same samples was 257
of 282 cases (91.1%) [19]. In the current study, the degree of concor-
dance between the HDC and the HC2 was 98.5% (Cohen's kappa,
0.659 [substantial agreement]). In our previous study involving the
concordance of both HPV tests in patients with CIN2–3, the overall
agreement between the 2 tests was 97.3%, with a kappa value of
0.815 (near-perfect agreement) [17]. Of 652 HPV-positive specimens
by the HC2, the HDC was positive in 644 specimens (98.8%). Among
20 specimens that were negative by the HC2, the HDC was negative
in 10 specimens (50.0%). The HPV detection rate determined by the
HDC was comparable to that determined by the HC2 in patients
with invasive cervical cancer and its precursors.
The current studywas the ﬁrst study to examine vaccinated patients
who underwent treatment for CIN2–3. Despite the limitations of ana-
lyzing the retrospective data, our results indicate that vaccination
with the quadrivalent HPV vaccine among patients aged 20–45 years
who had surgical treatment for CIN2–3 is effective in preventing recur-
rent CIN2–3. After treatment for CIN2–3, women are at increased risk
for recurrent disease in the long run, and those with vaccination had a
signiﬁcantly reduced risk of recurrent CIN2–3. Our analysis also showed
that vaccination after treatment of CIN2–3 signiﬁcantly reduced the risk
of recurrence in patients related to vaccine HPV types (types 16 and 18)
and that the quadrivalent HPV vaccine is the prophylactic vaccine for
recurrent CIN2–3.
A randomized, placebo-controlled, double-blind, and efﬁcacy study
is required to conﬁrm that vaccination prevents recurrent disease in pa-
tientswho underwent treatment for CIN2–3 and to deﬁne the appropri-
ate time to start the ﬁrst dose of quadrivalent HPV vaccination after
LEEP for women who missed the opportunity of vaccination before de-
veloping the disease.Role of the funding source
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